Enliven holder plans $2.25M stock resale

A trust associated with former Enliven Therapeutics director Richard A. Heyman filed to sell 38,000 ELVN shares under Rule 144.

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. (ELVN) is the issuer for a planned resale of its common stock under Rule 144 by Richard A. Heyman, through a trust, with Fidelity Brokerage Services LLC acting as broker. The notice covers the proposed sale of 38,000 shares of common stock of Enliven.

The filing lists an aggregate market value of $2,252,830 for the shares to be sold and notes that Enliven had 60,904,946 shares outstanding of this class. The shares being sold originate from a prior stock option exercise for 15,418 shares and a restricted stock purchase agreement for 22,647 shares. The shares are held in the Richard A. Heyman and Anne E. Daigle Trust dated January 29, 2018, and are expected to be sold on the Nasdaq market.

Key Figures

Shares to be sold: 38,000 shares Aggregate market value of shares to be sold: $2,252,830 Shares outstanding: 60,904,946 shares +3 more

6 metrics

Shares to be sold 38,000 shares Common stock proposed for sale under Rule 144

Aggregate market value of shares to be sold $2,252,830 Value of 38,000 ELVN common shares covered by the notice

Shares outstanding 60,904,946 shares Enliven Therapeutics common shares outstanding for this class

Shares from stock option exercise 15,418 shares Originating from Stock Options Exercise dated October 23, 2020

Shares from restricted stock purchase 22,647 shares Originating from Restricted Stock Purchase agreement dated January 2020

Date of notice September 4, 2026 Date the Form 144 notice was filed

Key Terms

Rule 144, Stock Options Exercise, Restricted Stock Purchase agreement, trust, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Options Exercise financial

"Common | 10/23/2020 | Stock Options Exercise | ELVN"

Restricted Stock Purchase agreement financial

"Common | 01/28/2020 | Restricted Stock Purchase agreement | ELVN"

trust financial

"shares are being sold from RICHARD A HEYMAN AND ANNE E DAIGLE TR, U/A 1/29/18"

A trust is a legal setup in which one party (the trustee) holds and manages assets—like cash, stocks or property—on behalf of other people (beneficiaries) according to instructions from the person who created it (the grantor). Think of it as a locked box with a keyholder who must follow written rules; for investors it matters because trusts influence who controls and benefits from assets, affect taxes and succession, and can change how quickly or transparently shares are bought, sold or voted.

Form 144 regulatory

"144: Securities Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

What does the Form 144 filing mean for Enliven Therapeutics (ELVN)?

The Form 144 reports a planned resale of 38,000 ELVN common shares by a shareholder under Rule 144. It discloses an intended sale by an existing holder and does not represent a new issuance of shares by Enliven Therapeutics.

How many Enliven Therapeutics (ELVN) shares are proposed to be sold?

The notice states that 38,000 shares of Enliven Therapeutics common stock are proposed to be sold through Fidelity Brokerage Services LLC on the Nasdaq market under Rule 144.

What is the reported market value of the ELVN shares in this Form 144?

The filing lists an aggregate market value of $2,252,830 for the 38,000 ELVN shares covered by the notice, based on the market price information used in the Form 144 disclosure.

How many Enliven Therapeutics (ELVN) shares are outstanding according to this filing?

The Form 144 reports that there are 60,904,946 Enliven Therapeutics common shares outstanding, providing context for the size of the proposed 38,000-share resale.

Who is selling the ELVN shares and through what account?

The planned sale is for the account of Richard A. Heyman, with the shares held by the Richard A. Heyman and Anne E. Daigle Trust, U/A 1/29/18. Fidelity Brokerage Services LLC is listed as the broker handling the transaction.

What are the sources of the ELVN shares being sold under this Form 144?

The filing states that the shares come from a Stock Options Exercise dated October 23, 2020 for 15,418 shares and a Restricted Stock Purchase agreement dated January 2020 for 22,647 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 02:59 PM Accepted by SEC EDGAR 09/04/2026 - 02:58 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001584759
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	205 PARK ROAD BURLINGAME CALIFORNIA 94010
Phone	650-547-5814
Name of Person for Whose Account the Securities are To Be Sold	Heyman Richard A.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	resigned from BOD

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 245 Summer Street Boston MA 02110	38000	2252830.00	60904946	09/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/23/2020	Stock Options Exercise	ELVN			15418	10/23/2020	N/A
Common	01/28/2020	Restricted Stock Purchase agreement	ELVN			22647	01/25/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	shares are being sold from RICHARD A HEYMAN AND ANNE E DAIGLE TR, U/A 1/29/18
Date of Notice	09/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Audrey Skillern, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Richard Heyman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)